述评：儿科人群中药物代谢酶个体发生信息的众多异常：儿科人群个体化药物治疗的障碍
Commentary: A Myriad Aberrations on Information of Ontogeny of Drug Metabolizing Enzymes in the Pediatric Population: An Obstacle for Personalizing Drug Therapy in the Pediatric Population.
作者信息
Uppugunduri Chakradhara Rao S, Ansari Marc
机构信息
Department of Pediatrics, Geneva University Hospitals, Geneva, Switzerland.
出版信息
Drug Metab Lett. 2016;10(2):72-4. doi: 10.2174/1872312810666160224143443.
Abstract
Major lacunae exist in our understanding of how developmental changes in drug biotransformation influence drug's exposure and thus its efficacy and toxicity in children. It is not just about smaller weight in children, which modifies the pattern of the drug's exposure. There are developmental, functional changes in organ systems, liver to body mass ratios, and changes in metabolism. Understanding these changes and conducting studies to obtain data on ontogeny of drug metabolizing enzymes is essential for implementation of personalized dosing schedules in the pediatric population.
摘要
在我们对药物生物转化的发育变化如何影响药物暴露，进而影响其在儿童中的疗效和毒性的理解方面，存在重大空白。这不仅仅是儿童体重较轻改变了药物暴露模式的问题。器官系统存在发育性的功能变化、肝脏与体重的比例变化以及代谢变化。了解这些变化并开展研究以获取药物代谢酶个体发育的数据，对于在儿科人群中实施个性化给药方案至关重要。
相似文献
1
Commentary: A Myriad Aberrations on Information of Ontogeny of Drug Metabolizing Enzymes in the Pediatric Population: An Obstacle for Personalizing Drug Therapy in the Pediatric Population.述评：儿科人群中药物代谢酶个体发生信息的众多异常：儿科人群个体化药物治疗的障碍
Drug Metab Lett. 2016;10(2):72-4. doi: 10.2174/1872312810666160224143443.
2
Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units.DMET 个体发育对新生儿和儿科重症监护病房常用药物处置的潜在影响。
Expert Opin Drug Metab Toxicol. 2021 Mar;17(3):273-289. doi: 10.1080/17425255.2021.1858051. Epub 2021 Jan 20.
3
Gene-Based Dose Optimization in Children.基于基因的儿童剂量优化。
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:311-331. doi: 10.1146/annurev-pharmtox-010919-023459. Epub 2019 Jul 5.
4
Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children.药物代谢酶的发育性表达：对新生儿和幼儿处置的影响。
Int J Pharm. 2013 Aug 16;452(1-2):3-7. doi: 10.1016/j.ijpharm.2012.05.079. Epub 2012 Jul 3.
5
Pharmacotherapy during pediatric extracorporeal membrane oxygenation: a review.小儿体外膜肺氧合期间的药物治疗：综述
Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1133-42. doi: 10.1080/17425255.2016.1201066. Epub 2016 Jul 1.
6
The Effects of Obesity on Drug Metabolism in Children.肥胖对儿童药物代谢的影响。
Drug Metab Lett. 2015;9(2):88-98. doi: 10.2174/1872312809666150804111612.
7
Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.儿科药物治疗中的建模与模拟：药物代谢动力学在确定儿童正确剂量中的应用。
Clin Pharmacol Ther. 2015 Sep;98(3):298-308. doi: 10.1002/cpt.169. Epub 2015 Jul 20.
8
Ontogeny of drug metabolizing enzymes in the neonate.新生儿药物代谢酶的个体发生
Semin Fetal Neonatal Med. 2005 Apr;10(2):123-38. doi: 10.1016/j.siny.2004.11.001. Epub 2005 Jan 25.
9
Pharmacogenomics for Drug Dosing in Children: Current Use, Knowledge, and Gaps.儿童药物剂量的药物基因组学：当前的使用、知识和差距。
J Clin Pharmacol. 2021 Jun;61 Suppl 1(Suppl 1):S188-S192. doi: 10.1002/jcph.1891.
10
The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children.儿童药物代谢酶的发育及其对药物不良反应易感性的影响。
Toxicology. 2003 Oct 1;192(1):37-48. doi: 10.1016/s0300-483x(03)00249-x.
引用本文的文献
1
Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?神经母细胞瘤的药物遗传学：已经可以临床实施的和即将到来的？
Int J Mol Sci. 2021 Sep 10;22(18):9815. doi: 10.3390/ijms22189815.
2
Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use.儿科肿瘤学中的药物基因组学：临床应用的基因-药物关联综述。
Int J Mol Sci. 2016 Sep 8;17(9):1502. doi: 10.3390/ijms17091502.
本文引用的文献
1
Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model.虚拟儿科药代动力学试验中个体药物非依赖性系统参数的变化：将时变生理学引入儿科 PBPK 模型。
AAPS J. 2014 May;16(3):568-76. doi: 10.1208/s12248-014-9592-9. Epub 2014 Apr 4.
2
A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.基于体内数据对细胞色素P450 1A2和3A4个体发育功能的重新评估与验证
Clin Pharmacokinet. 2014 Jul;53(7):625-36. doi: 10.1007/s40262-014-0140-7.
3
Ontogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies.哺乳动物代谢酶在人和毒理学研究中动物的个体发生。
Crit Rev Toxicol. 2012 May;42(5):323-57. doi: 10.3109/10408444.2012.674100.
4
Cytostatic drugs in infants: a review on pharmacokinetic data in infants.婴儿期的细胞毒性药物：婴儿药代动力学数据综述。
Cancer Treat Rev. 2012 Feb;38(1):3-26. doi: 10.1016/j.ctrv.2011.03.005. Epub 2011 Apr 13.
5
Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother.一位服用可待因母亲的母乳喂养新生儿吗啡中毒的药物遗传学
Lancet. 2006 Aug 19;368(9536):704. doi: 10.1016/S0140-6736(06)69255-6.
6
Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre- and postnatal human liver.芳基、雌激素和羟基类固醇硫酸转移酶在人肝脏产前和产后的发育表达。
J Pharmacol Exp Ther. 2006 Mar;316(3):1310-7. doi: 10.1124/jpet.105.093633. Epub 2005 Dec 9.
7
Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses.新生儿使用氯霉素。过量使用时其毒性的生理学解释。
N Engl J Med. 1960 Apr 21;262:787-94. doi: 10.1056/NEJM196004212621601.
8
Developmental pharmacology--drug disposition, action, and therapy in infants and children.发育药理学——婴幼儿的药物处置、作用及治疗
N Engl J Med. 2003 Sep 18;349(12):1157-67. doi: 10.1056/NEJMra035092.
9
Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.婴儿肝脏和肾脏全身清除途径的个体发生：第二部分。
Clin Pharmacokinet. 2002;41(13):1077-94. doi: 10.2165/00003088-200241130-00005.
10
Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies.儿科门诊/住院患者药物不良反应的发生率：前瞻性研究的系统评价和荟萃分析
Br J Clin Pharmacol. 2001 Jul;52(1):77-83. doi: 10.1046/j.0306-5251.2001.01407.x.
Zotero 插件